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Purpose: To determine whether β-adrenergic receptors require insulin receptor substrate (IRS)-1 activity to regulate
apoptosis in retinal Müller cells.
Methods: Müller cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) medium grown in normal (5 mm)
or high glucose (25 mM) conditions. The medium was supplemented with 10% fetal bovine serum and antibiotics. Cells
were allowed to reach 80%–90% confluence. After becoming appropriately confluent, cells were placed in medium with
reduced serum (2%) for 18–24 h to eliminate any effects of fetal bovine serum. Cells were then transfected with 10 ug of
IRS-1 small hairpin RNA (shRNA). Forty-eight hours following transfection, cells were lysed and harvested for protein
analysis using western blotting. In additional experiments, some cells were treated with 10 uM salmeterol for 24 h
following transfection with IRS-1 shRNA. To determine whether IRS-1 directly regulates apoptotic events in the insulin-
signaling pathway in retinal Müller cells, a cell death assay kit was used. In tumor necrosis factor (TNF)α inhibitory
studies, cells were treated with 5 ng/ml of TNFα alone for 30 min or 30 min pretreatment with TNFα followed by salmeterol
for 4 h.
Results:  Müller  cells  treated  with  5  ng/ml  TNFα  in  25  mM  glucose  significantly  increased  phosphorylation  of
IRS-1Ser307.  Treatment  with  the  selective  beta-2-adrenergic  receptor  agonist,  salmeterol,  significantly  decreased
phosphorylation of IRS-1Ser307. Following IRS-1 shRNA transfection+salmeterol treatment, Bcl-2–associated X protein
(Bax) and cytochrome c levels were significantly decreased. Salmeterol+IRS-1 shRNA also decreased cell death and
increased protein levels of B-cell lymphoma-extra large (Bcl-xL), an anti-apoptotic factor.
Conclusions: In these studies, we show for the first time that salmeterol, a beta-2-adrenergic receptor agonist, can reduce
retinal Müller cell death through IRS-1 actions. These findings also suggest the importance of IRS-1 in beta-adrenergic
receptor signaling in the prevention of cell death in retinal Müller cells.
Over the years, it has been widely accepted that changes
that occur in the diabetic retina occur in response to a variety
of  insults,  including  high  glucose,  oxidative  stress,  and
increased expression of inflammatory markers [1-11]. During
the initial stages of diabetic retinopathy, Müller cells become
activated and express increased glial fibrillary acidic protein
levels in diabetes [4,5,11-15]. This increase in glial fibrillary
acidic protein levels signals a transition of Müller cells from
a quiescent to a reactive state, causing a dysfunction in the
regulation  of  inflammatory  markers,  glucose  transport,
oxidative stress, growth factors, and cell survival [4,5,11,
15-18].  In  diabetic  retinopathy,  the  regulation  of  insulin
signaling,  specifically  that  of  insulin  receptor  substrate
(IRS)-1),  is  not  well  understood.  IRS-1  is  a  180  kDa
downstream  substrate  of  the  insulin  receptor  and  plays  a
central role in both insulin and insulin-like growth factor
(IGF-1) signaling [19-23]. IRS-1 has been shown to have
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numerous sites for phosphorylation by serine, threonine, and
tyrosine, with some sites serving to propagate insulin/IGF-1
receptor signaling, while other residues inhibit insulin/IGF-1
signaling. Tyrosine phosphorylation of IRS-1 is known to be
an important step in the propagation of the insulin/IGF-1
signal, while the role of serine and threonine phosphorylation
of  IRS-1  has  recently  become  of  more  significance  as  a
component  of  insulin  resistance,  since  decreased  insulin/
IGF-1 signaling is likely a key factor in diabetes [19-23]. One
of the serine residues on IRS-1 that has been suggested to
serve an inhibitory role in insulin signaling is serine 307
[19,23,24]. Previous studies have shown that increases in the
phosphorylation  of  IRS-1Ser307  causes  decreased  insulin
receptor  signaling,  resulting  in  increased  in  apoptosis  in
various tissues throughout the body [23-31].
In vitro and in vivo studies have shown that prolonged
exposure to a hyperglycemic environment produces several
cellular  changes,  including  increased  apoptosis  [32,33].
Normal regulation of cell death in the mitochondria is tightly
controlled by the B-cell lymphoma 2 (Bcl-2) family, both pro-
and antiapoptotic members [10,34-39]. In a disease such as
diabetic retinopathy, where the hyperglycemic environment
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271causes cellular stress and damage, Bcl-2–associated X protein
(Bax), a member of the Bcl-2 family, can become activated
and form pores as a passage for other proapoptotic proteins to
be  released  [10,34-39].  Release  of  proteins,  such  as
cytochrome c, along with increased Bax levels results in cell
death through increased levels of key caspases. In contrast, B-
cell lymphoma-extra large (Bcl-xL), an antiapoptotic member
of  the  Bcl-2  family,  is  known  to  prevent  cell  death  by
inhibiting activation of the proapoptotic proteins [35,37-39].
These changes have been well studied in other diseases, as
well  as  other  cell  types  in  diabetic  retinopathy  [34,36].
However, the regulation of apoptotic proteins in retinal Müller
cells is not well characterized. Furthermore, the potential role
for IRS-1 in this pathway in the regulation of Bax, cytochrome
c, and Bcl-xL has not been investigated.
In this investigation, we hypothesize that silencing the
expression  of  IRS-1  will  demonstrate  that  IRS-1  directly
regulates specific apoptotic markers in retinal Müller cells.
Additionally,  since  we  have  previously  demonstrated  that
beta-adrenergic receptors can decrease tumor necrosis factor
(TNF)α  levels  [40],  and  TNFα  is  known  to  increase
IRS-1Ser307,  we  hypothesize  that  salmeterol,  a  beta-2-
adrenergic  receptor  agonist,  requires  IRS-1  actions  to
decrease apoptosis of retinal Müller cells.
METHODS
Müller cell culture: Rat retinal Müller cells (rMC-1) were
cultured and passaged in Dulbecco's Modified Eagle Medium
(DMEM) medium (HyClone, Logan, UT) containing 5 mM
glucose (normal glucose) or 25 mM glucose (high glucose),
10% fetal bovine serum (FBS), and 2 mM L-glutamine. Once
the cells reached 80% confluency, the concentration of FBS
was decreased from 10% to 2% in 25 mM media starved cells.
Cells remained in this starved environment for 18–24 h to
reduce any serum effects from the medium. Immediately after
starvation, cells were treated with 10 μM salmeterol (beta-2-
adrenergic  receptor  agonist)  dissolved  into  high  glucose
medium for 6 h. Additionally, a specific number of dishes
were used as untreated controls for both treatments in both
25 mM glucose and 5 mM glucose for the duration of the
treatment.  Following  treatment,  cells  were  harvested  and
pelleted in lysis buffer.
Tumor  necrosis  factor–α  inhibitory  studies:  In  TNFα
inhibitory studies, cells were treated with 5 ng/ml of TNFα
alone for 30 min or 30 min pretreatment with TNFα followed
by 10 μM salmeterol for 4 h. Immediately after treatments,
cells were lysed with lysis buffer (1.58 g Tris base, 150 ml
sterile water, 1.80 g NaCl, 20 ml 10% Igepal-40, 5 ml 10%
Na-deoxycholate, 2 ml 100 mM EDTA, and 1 μg protease
inhibitors  (all  ingredients  for  lysis  buffer;  Sigma,  Sigma-
Aldrich Corp, St. Louis, MO) and harvested at each of the
treatment time points.
shRNA library construction: The sequence for each of the 21
bp shRNA constructs was designed using Invitrogen Block-
iT RNA designer™ (Invitrogen, Carlsbad, CA). The sequence
for rat IRS-1 (accession # NM_012969) was 5'-CGA GTT
CTG  GAT  GCA  AGT  GGA  and  the  sequence  of  the
scrambled shRNA was 5'-GAC GAA CCC CTG TTC CGA
ATG. The Mir algorithm was used to design double-stranded
cDNAs. For rat IRS-1, the sequence of the forward primer was
5′-TGC TGT CCA CTT GCA TCC AGA ACT CG GTT TTG
GCC ACT GAC TGA CCG AGT TCT ATG CAA GTG
GA-3′ and its complementary strand was 5′-CCT GTC CAC
TTG CAT AGA ACT CGG TCA GTC AGT GGC CAA AAC
CGA GTT CTG GAT GCA AGT GGA C-3′. These synthetic
oligo constructs were hybridized and cloned into BLOCK-
iT™ Pol II miR RNAi Expression Vector with EmGFP. Each
plasmid was grown on agar plates containing 50 µg/ml of
spectinomycin.  Colonies  were  selected  and  sequenced  to
verify insert sequence, and then a large plasmid preparation
was made using Qiagen kits (Qiagen, Baltimore, MD). Upon
transient transfection into cells, expression of the shRNA was
monitored by green fluorescent protein (GFP) fluorescence
(λex=488 nm, λem=520 nm).
To determine the effect of transient expression of 5 μg of
each shRNA/60 mm plate on its target, we probed total RNA
by  reverse  transcriptase  (RT)–PCR  or  protein  by  western
blotting using the anti-IRS-1 antibody (SC-559; Santa Cruz
Biotechnology, Santa Cruz, CA). For the RT–PCR procedure,
first-strand  cDNA  synthesis  was  performed  using  the
Transcriptor First-Strand cDNA Synthesis Kit from (Roche
Diagnostics, Indianapolis, IN) using 62 ng of RNA per assay.
The  RT–PCR  primers  were  designed  using  a  web-based
design center (Universal prolibrary). The mRNA level for
each protein was quantified using the Universal prolibrary of
short hydrolysis-locked nucleic acid probes in combination
with  the  primers.  The  quantification  of  mRNA  was
accomplished  using  the  Roche  Lightcycler  480  Real-time
PCR system and software (Roche diagnostics).
RNA interference transfection: For shRNA studies, cells were
passaged and cultured until 80% confluency, at which time
cells were transfected with shRNA to silence IRS-1 using
lipofectamine for 24 h. For IRS-1 shRNA + salmeterol studies,
following the 24 h of transfection, cells were treated with 10
μM salmeterol for an additional 6 h. Cells that were designated
as  IRS-1  shRNA  alone  were  harvested  with  no  further
treatment  following  the  24  h  transfection  period.  For
scrambled  shRNA  studies,  cells  were  transfected  with
scrambled shRNA using lipofectamine for 24 h.
Western blot analysis: Cells stored in lysis buffer containing
protease inhibitors (leupeptin 1 μg/ml, aprotinin 1 μg/ml) were
homogenized,  sonicated,  and  protein  concentrations  were
determined  by  Bradford  assay  (Thermo  Fisher  Scientific,
Rockford, IL). Denaturing sample buffer (2× glass distilled
water  [GDW],  1M  Tris-HCL  pH  6.8,  30%  glycerol,  β-
mercaptoethanol,  0.05%  bromophenol  blue,  and  0.125  g
recrystallized sodium dodecyl sulfate [SDS]) was added to
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27230–50 μg of protein and loaded onto 10%–20% precast tris-
glycine  gels  (Invitrogen,  Carlsbad,  CA)  for  separation,
followed  by  transfer  to  nitrocellulose  membranes.
Membranes were blocked overnight at 4 °C with 5% BSA and
with the following primary antibodies: IRS-1 Ser307 (diluted
1:500; Cell Signaling, Beverly, MA), total IRS-1 (diluted
1:500; Cell Signaling), Bcl-xL (diluted 1:500; Cell Signaling),
Bax (diluted 1:500; Cell Signaling), Akt (diluted 1:500; Cell
Signaling), and cytochrome c (diluted 1:500; Cell Signaling).
All blots were washed and then incubated at room temperature
with  the  appropriate  secondary  antibodies  conjugated  to
horseradish  peroxidase  at  1:5,000  dilutions.  Following
secondary  antibodies,  blots  were  washed  and  placed  into
enhanced  chemiluminescence  (ECL)  reagent  (Pierce,
Rockford,  IL)  for  chemiluminescent  detection  using  the
Kodak  ImageStation  4000MM  (Rochester,  NY).  Mean
densitometry of immunoreactive bands was assessed using
Kodak software, and results were expressed in densitometric
units and compared to control groups for each individual
experiment.
Cell death assays: Cell death was assessed in rMC-1 cells
using a cell death assay kit (Roche Diagnostics) following the
manufacturer’s  instructions.  Müller  cell  lysates  were
transferred  into  a  streptavidin-coated  microplate  that  was
provided  by  manufacturer.  Mixtures  of  anti-histone-biotin
and anti-DNA-POD antibodies were added to the cells for a
short incubation periods. During these periods, the mixture
was allowed to bind the nucleosomes and histones of cells
plated. Following incubation, washing took place to remove
any antibodies that did not bind during the incubation period.
Following these steps, plates were measured according to
manufacturer's  instructions.  This  assay  measures  histone-
associated DNA fragments in a quantitative manner in retinal
Müller cells. Analysis from these experiments was performed
using  absorbance  values  obtained  at  the  appropriate
wavelength,  followed  by  statistics  using  Prism  4.0  with
comparisons between the control and treatment groups using
Mann–Whitney as a post-hoc test with p<0.05 being accepted
as significant.
Statistical  analysis:  All  statistical  analyses  for  these
investigations  were  obtained  using  Prism  4.0b  software.
Nonparametric  tests  were  conducted  for  cell  culture
experiments due to the small sample size for each experiment.
For all experiments, the 5 mM (#) and 25 mM (*) glucose
samples (controls) were compared to IRS-1 shRNA treatment
groups  and  salmeterol  treatment  groups  using  a  Mann–
Whitney  U  test,  with  p<0.05  considered  as  significantly
different. Additionally, a separate comparison was conducted
with IRS-1 shRNA treatment + salmeterol versus salmeterol
treatment alone ($).
RESULTS
Salmeterol  prevents  phosphorylation  levels  of  IRS-1Ser307
induced by tumor necrosis factor–α: It is known that TNFα
preferentially phosphorylates IRS-1Ser307 in other cell types
[23,26,27,30,31]; we wanted to see if the same mechanism
occurs  in  retinal  Müller  cells.  Following  treatment  with
salmeterol,  western  blot  analysis  revealed  that
phosphorylation of IRS-1Ser307 was significantly decreased as
compared  to  cells  without  treatment  or  with  TNFα-only
treatment (Figure 1, *p<0.05 versus not treated, # p<0.05
versus TNFα alone).
Silencing of IRS-1 decreases total Akt levels: Previous data
has  shown  that  increases  in  tyrosine  phosphorylation  of
insulin receptor results in increased Akt phosphorylation via
IRS-1.  Knockdown  of  IRS-1  with  shRNA  (Figure  2A,
Figure  1.  Ratio  of  insulin  receptor
substrate (IRS)-1Ser 307 in Müller cells. A
phosphorylation  of  IRS-1Ser307  is
significantly increased in Müller cells
following treatment with tumor necrosis
factor–α,  but  treatment  with  beta-2-
adrenergic receptor agonist, salmeterol
significantly decreases phosphorylation
levels. Significance was determined by
one-tailed,  nonparametric  Mann–
Whitney  test  on  western  blot  data
(*p<0.05  versus  high  glucose,  n=4,
#p<0.05 versus normal glucose, n=4).
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273*p<0.05 versus 25 mM glucose) showed a significant decrease
in total Akt levels (Figure 2B, *p<0.05 versus 25 mM glucose)
cultured  in  a  hyperglycemic  environment.  These  results
suggest that IRS-1 signals to Akt in retinal Müller cells.
Loss of IRS-1 increases cell death in retinal Müller cells:
Treatment of cells with salmeterol alone prevented cell death
in  retinal  Müller  cells  (Figure  3,  p<0.05  versus  25  mM
glucose). Cell death analyses showed a significant increase in
response to silencing of IRS-1 in cells cultured in high glucose
versus  normal  glucose  (Figure  3,  #p<0.05  versus  5  mM
glucose). Salmeterol + IRS-1 shRNA showed a significant
increase in cell death compared to salmeterol alone (Figure 3,
$p<0.05  versus  salmeterol  alone),  suggesting  that  beta-
adrenergic receptors signal through IRS-1 to reduce cell death
in retinal Müller cells.
Silencing  IRS-1  increases  cytochrome  C  levels  in  retinal
Müller  cells:  Previous  studies  have  suggested  the
mitochondria as a key regulator of apoptosis, with excess
production of superoxides within the mitochondria initiating
cytochrome c being released from the cytosol to begin the
cascade  of  apoptotic  signaling  [35,37-39].  Our  current
investigation shows that prolonged exposure of retinal Müller
cells  to  hyperglycemia  results  in  the  excess  release  of
cytochrome C when compared to retinal Müller cells cultured
in  normal  glycemic  conditions  (Figure  4,  *p<0.05  versus
5  mM  glucose).  Western  blot  analysis  further  shows  that
salmeterol alone treatment significantly reduced cytochrome
C  levels,  with  the  effect  lessened  when  salmeterol  was
combined  with  IRS-1  shRNA  (Figure  4,  $p<0.05  versus
salmeterol alone). Taken together, these results suggest that
active IRS-1 is required for salmeterol to reduce cytochrome
C levels in retinal Müller cells cultured in a hyperglycemic
environment.
Absence of IRS-1 causes an increase in Bax levels: In addition
to cytochrome C, we also investigated another member of the
Bcl-2 family, Bax. Western blot analyses showed significant
Figure 2. Verification of insulin receptor
substrate (IRS)-1 shRNA knockdown.
A:  Mean  densitometry  and
representative  blot  of  IRS-1  levels
following  transfection  of  shRNA
(IRS-1)  in  rat  Müller  cells.  Mean
densitometry  was  done  for  each  blot
which  consisted  of  taking  the  mean
optical densities of 4 different western
blots for each protein analyzed. B: Mean
Densitometry of Akt levels following
transfection of shRNA (IRS-1) in Müller
cells. Significance was determined by
Mann–Whitney test (*p<0.05 versus 25
mM, n=5).
Figure 3. Cell death in insulin receptor
substrate (IRS)-1 knockdown. A: Cell
Death  ELISA  of  rat  Müller  cells
transfected  with  IRS-1  shRNA  alone
and IRS-1 shRNA + beta-2-adrenergic
receptor  agonist,  salmeterol  for  6  h.
Transfection  with  IRS-1  shRNA
significantly increased cell death levels
versus 5 mM glucose. Treatment with
salmeterol  (SALM)  alone  in  Müller
cells  significantly  decreased  levels  of
cell versus 5 mM glucose and 25 mM
glucose.  Statistical  significance  was
determined  Mann–Whitney  test
(*p<0.05  versus  25  mM  glucose,
#p<0.05 versus 5 mM glucose, $p<0.05
versus SALM n=5 for ELISA assay).
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274increases  in  Bax  protein  levels  in  high  glucose  samples
compared  to  normal  glucose  samples  (Figure  5,  #p<0.05
versus 5 mM glucose). Stimulation with salmeterol showed
that salmeterol could only reduce Bax when IRS-1 was active
(Figure 5, $p<0.05 versus salmeterol alone). These findings
were  in  agreement  with  previous  findings  that  suggested
increased Bax levels in a hyperglycemic environment [2,36];
however, to our knowledge, these results are the first to link
beta-adrenergic receptors and IRS-1 to Bax levels in retinal
Müller cells.
Antiapoptotic  Bcl-xL  is  reduced  with  the  loss  of  IRS-1:
Previous investigations suggest that IRS-1 plays a role in
antiapoptotic activities through proper control of the members
of the Bcl-2 family, such as Bcl-xL [2,36,41,42]. Mechanisms
of  the  interplay  between  IRS-1  and  Bcl-xL  are  unknown
[42]. Protein levels of Bcl-xL were significantly decreased in
high glucose samples compared to normal glucose samples
Figure  4.  Levels  of  cytochrome  C
increased in insulin receptor substrate
(IRS)-1 knockdown. Equal loading was
verified using ponceau staining. Mean
densitometry  was  done  for  each  blot
which  consisted  of  taking  the  mean
optical densities of 4 different western
blots for each protein analyzed. Mean
densitometry  displayed  a  significant
increase in cytochrome c levels cultured
in 25 mM glucose versus 5 mM glucose
samples. Knockdown of IRS-1 protein
significantly  increased  cytochrome  C
levels versus 5 mM and 25 mM glucose
samples. Western blot data showing that
treatment with salmeterol significantly
decreased  levels  of  proapoptotic
cytochrome C (*p<0.05 versus 5 mM
glucose  [NT],  $p<0.05  versus
salmeterol n=4 for western blot).
Figure 5. Bax protein levels increased in
insulin  receptor  substrate  (IRS)-1
knockdown. Protein levels of Bax were
significantly increased 25 mM glucose
versus  5  mM  glucose  samples.
Transfection of IRS-1 shRNA in Müller
cells  significantly  increased  levels  of
pro-apoptotic Bax. Salmeterol (10 uM)
significantly  decreased  Bax  levels
activity  after  6  h  of  treatment.
Significance  was  determined  by  the
Mann–Whitney test (*p<0.05 versus 25
mM glucose, $p<0.05 versus salmeterol
n=4, #p<0.05 versus 5 mM glucose, n=4
for  western  blot).  Equal  loading  was
verified using ponceau staining. Mean
densitometry  was  done  for  each  blot
which  consisted  of  taking  the  mean
optical densities of 4 different western
blots for each protein analyzed.
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275(Figure 6, #p<0.05 versus 5 mM glucose), suggesting that high
glucose promotes an apoptotic environment. Treatment with
salmeterol alone significantly increased Bcl-xL protein levels
compared to high glucose samples (Figure 6, *p<0.05 versus
25 mM glucose). Transfection of retinal Müller cells with
IRS-1 shRNA showed a significant decrease in protein levels
of  antiapoptotic  Bcl-xL  in  a  hyperglycemic  environment
(Figure 6, #p<0.05 versus 5 mM glucose). These findings
suggest beta-adrenergic receptor modulation of antiapoptotic
Bcl-xL, which would promote an antiapoptotic environment.
DISCUSSION
Previously, our laboratory has suggested that hyperglycemia
can  increase  inflammatory  cytokine  production  in  retinal
Müller cells [40]. The increase in inflammatory cytokines,
such  as  TNFα,  in  a  hyperglycemic  environment  was
significantly  reduced  when  cells  were  treated  with  the
nonselective beta-adrenergic receptor agonist, isoproterenol
[40]. These studies further suggested the presence of beta-
adrenergic receptors on retinal Müller cells, and that the loss
of beta adrenergic receptor signaling may be involved in the
increased inflammatory markers observed in hyperglycemia
[40]. Recent studies by other groups have identified a potential
role  for  inflammation  in  the  regulation  of  key  signaling
pathways  in  diabetes  [4,23-31,42-46].  These  studies  have
suggested that TNFα may mediate changes in insulin receptor
signaling by targeting downstream signaling proteins, such as
the IRS complex, to produce pathologic changes [4,23-31,
42-46].
The IRS complex proteins are responsible for mediating
the  downstream  actions  of  the  insulin  receptor.  The  IRS
complex consists of IRS 1–4, with each substrate playing a
significant role in the body; however, animal studies have
shown that a vast majority of insulin actions signal through
IRS-1 and IRS-2 [47]. The amino acid sequence of IRS-1
possesses  a  unique  signaling  mechanism  of  tyrosine
phosphorylation sites and serine phosphorylation sites [23,
28-31,42,44,46,48]  to  regulate  cellular  actions.
Phosphorylation of various tyrosine sites (Y99, Y1150, Y1151)
and several serine sites (Ser265, Ser302, Ser325, Ser358) increase
the downstream signaling mediated by IRS-1. In contrast,
other serine residues (such as Ser307, Ser636, Ser639) have been
shown to inhibit signaling downstream of IRS-1, suggesting
that  IRS-1  phosphorylation  may  be  a  key  regulator  for
activation or inhibition of a multitude of signaling cascades.
Based on the literature on other cell types, with the onset
of  diabetes,  TNFα  preferentially  phosphorylates  Ser307  on
IRS-1 [6,48,49]. Phosphorylation of IRS-1Ser307 can play an
inhibitory role in insulin/IGF-1 receptor signal transduction,
potentially leading to the increased apoptosis noted in the
diabetic retina [6,48,49]. The present findings in Müller cells
(Figure 1) confirm work in adipose tissue cells, suggesting
that TNFα negatively regulates insulin receptor signaling by
phosphorylating Ser307 on IRS-1 to inhibit insulin action [6,
48].  In  these  studies,  we  began  using  a  selective  beta-2-
adrenergic  receptor  agonist,  salmeterol,  to  selectively
stimulate  the  beta-2-adrenergic  receptor,  since  we  have
recently found that this receptor is active in retinal Müller
cells. Our findings in this study with salmeterol demonstrate
that  beta-2-adrenergic  receptor  stimulation  may  inhibit
cytokine  release  in  retinal  Müller  cells  cultured  in  a
hyperglycemic environment, resulting in reduced IRS-1Ser307
phosphorylation, thereby leading to decreased apoptosis.
Additionally, we investigated whether beta-adrenergic
receptors regulate apoptosis of retinal Müller cells through
IRS-1  signaling.  Since  we  know  that  beta-adrenergic
receptors  can  decrease  cell  death  in  a  high  glucose
environment  [50],  we  sought  to  determine  whether
modulation of IRS-1 was involved. Knockdown of IRS-1
Figure 6. Anti-apoptotic Bcl-xL levels
decreased in insulin receptor substrate
(IRS)-1  knockdown.  Western  blot
analysis  showing  significantly
decreased levels of Bcl-xL versus 5 mM
glucose and 25 mM glucose. Salmeterol
treatment significantly increased levels
of  Bcl-xL  toward  basal  levels.  Equal
loading  was  verified  using  ponceau
staining. Mean densitometry was done
for each blot which consisted of taking
the mean optical densities of 4 different
western blots for each protein analyzed.
Significance  was  determined  by  one-
tailed,  nonparametric  Mann–Whitney
tests  on  western  blot  data  (*p<0.05
versus 25 mM Glucose, $p<0.05 versus
salmeterol n=4, #p<0.05 versus 5 mM
Glucose, n=4).
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276showed  a  significant  increase  in  cell  death  compared  to
samples  in  5  mM  glucose,  but  stimulation  of  the  beta-2-
adrenergic  receptor  with  salmeterol  prevented  cell  death
through IRS-1 in a hyperglycemic environment on retinal
Müller cells.
Several factors can influence the increase in apoptosis.
An  imbalance  in  the  expression  of  antiapoptotic  versus
proapoptotic  members  of  the  Bcl-2  family  within  the
mitochondria of retinal Müller cells is one possibility. Retinal
Müller cell samples cultured in a 25 mM glucose environment
showed a significant increase in cytochrome C and Bax levels
compared to samples cultured in 5 mM glucose. We found
that activation of cytochrome C and Bax in a hyperglycemic
environment  was  reduced  following  treatment  with
salmeterol. Increases in cytochrome C and Bax were also
demonstrated with IRS-1 shRNA + salmeterol, indicative of
increased cell death following knockdown of IRS-1 versus
cells treated with salmeterol alone. Our results suggest that
beta-adrenergic receptors play a specific role in the regulation
of key apoptotic markers through alterations in IRS-1 levels.
In support of this finding, we also found that high glucose
decreased antiapoptotic Bcl-xL, but treatment with salmeterol
significantly  increased  Bcl-xL  in  a  hyperglycemic
environment. Decreased Bcl-xL levels were also observed in
IRS-1  shRNA  +salmeterol  treatments,  suggesting  that  the
antiapoptotic effects of Bcl-xL restored with treatment of
salmeterol required IRS-1 for activation.
To our knowledge, our research is the first to report that
salmeterol, a beta-2-adrenergic receptor agonist, can reduce
cell  death  activity  in  retinal  Müller  cells  using  IRS-1
signaling. However, our results are not in agreement with
previous results that suggest that IRS-2 is the key mediator of
cell death in whole retinal samples [44,45]. The discrepancies
in our findings in relation to those of previous studies likely
stem from the fact that we concentrated solely on in vitro
studies using retinal Müller cells. Previous studies have dealt
with in vivo and ex vivo experiments using whole retinal
samples, which contain a variety of retinal cell types. In other
work from our laboratory [50], we have found differences in
insulin receptor substrate signaling in retinal endothelial cells,
which  tend  to  signal  through  an  IGF-1  receptor/IRS-2-
dependent mechanism [50]. Thus, it appears that different cell
types  in  the  retina  may  use  different  IRS  complexes  for
cellular signaling, which expands the signaling possibilities
of retinal cells.
While we recognize that IRS-1 is a key component of
insulin signaling, we chose to focus our investigations on beta-
adrenergic receptor regulation of apoptosis of retinal Müller
cells through the actions of IRS-1 rather than insulin receptor
or IGF-1 receptor actions. Future studies may be directed at
beta-adrenergic receptor actions and cross talk with insulin
signaling.
In summary, these studies demonstrate that retinal Müller
cells  cultured  in  an  hyperglycemic  environment  activate
several mechanisms leading to increased cell death; 1) the
initial mechanism involves increases in phosphorylation of
IRS-1Ser307, mediated by increased TNFα levels in the diabetic
retina  [7];  2)  the  second  mechanism  involves  significant
increases  in  apoptotic  markers  Bax  and  cytochrome  C,
coupled with a significant decrease in antiapoptotic Bcl-xL.
Both mechanisms of cell death were significantly inhibited
following treatment with a beta-2-adrenergic receptor agonist,
salmeterol. Taken together, these results suggest that beta-
adrenergic receptors require active IRS-1 to prevent cell death
in retinal Müller cells.
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